10-Q: Labcorp Reports First Quarter 2025 Results: Revenue Up 5.3% Driven by Acquisitions and Organic Growth

Labcorp's Q1 2025 revenue increased by 5.3% year-over-year, driven by acquisitions and organic growth, despite unfavorable foreign currency translation.

Summary

• Labcorp's Q1 2025 revenues reached $3,345.1 million, a 5.3% increase compared to $3,176.6 million in Q1 2024.
• The revenue increase was driven by acquisitions (3.7%) and organic growth (2.1%), partially offset by unfavorable foreign currency translation (0.5%).
• Diagnostics Laboratories (Dx) revenues increased by 6.0% to $2,629.6 million, while Biopharma Laboratory Services (BLS) revenues increased by 1.5% to $721.3 million.
• Cost of revenues increased by 5.2% to $2,397.1 million, but as a percentage of revenues, it decreased slightly to 71.7% from 71.8% in the prior year.
• Selling, general, and administrative expenses increased by 7.4% to $546.0 million, representing 16.3% of revenues compared to 16.0% in the prior year.
• Net earnings attributable to Labcorp Holdings Inc. were $212.8 million, compared to $228.0 million in the same period last year.
• Basic earnings per share were $2.54, and diluted earnings per share were $2.52.
• The company acquired several businesses for cash of $53.5 million during the quarter, with preliminary purchase considerations allocated to net assets, including $41.1 million in identifiable intangible assets.
• Labcorp completed the acquisition of a 15% minority interest in SYNLAB for approximately $151.6 million, accounted for as an equity method investment.
• The company announced an agreement to acquire select assets of BioReference Health's laboratory business, focused on oncology, for up to $225.0 million, expected to close in the second half of 2025.
• The company paid $1,000.0 million on senior notes due February 2025 and received $225.0 million from its accounts receivable securitization facility.
• The company's cash and cash equivalents totaled $369.4 million at March 31, 2025.
• The company has outstanding authorization from its board of directors to purchase up to $1,280.4 million of its common stock.
• A cash dividend of $0.72 per share was declared and paid during the quarter, and another dividend of the same amount was announced for June 11, 2025.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive revenue growth offset by increased expenses and legal challenges. The outlook is stable, but risks remain.

Positives

• Revenue increased by 5.3% year-over-year, indicating growth in the business.
• Acquisitions and organic growth contributed positively to revenue.
• Dx and BLS segments both experienced revenue growth.
• The company completed the acquisition of a 15% minority interest in SYNLAB.
• The company announced an agreement to acquire select assets of BioReference Health's oncology-focused laboratory business.
• The company has authorization to repurchase up to $1,280.4 million of its common stock.
• The company declared and paid a cash dividend of $0.72 per share.

Negatives

• Unfavorable foreign currency translation negatively impacted revenue by 0.5%.
• Net earnings attributable to Labcorp Holdings Inc. decreased compared to the same period last year.
• Selling, general, and administrative expenses increased as a percentage of revenues.
• Equity method (loss) income, net decreased due to losses from investments made prior to 2025.

Risks

• The document mentions numerous risk factors that could affect future performance, including changes in regulations, competition, litigation, and economic conditions.
• The company is involved in various legal proceedings, including a patent infringement lawsuit with a significant damage award against the company, which it is appealing.
• The company faces risks related to cybersecurity incidents, as highlighted by the AMCA incident and related lawsuits.
• The company is subject to risks related to compliance with various laws and regulations, including healthcare regulations and data privacy laws.

Future Outlook

The company expects to maintain a consistent level of capital spending for the remainder of 2025, primarily in connection with projects to support growth in the Companys core businesses, facility expansion and updates, projects related to its LaunchPad initiative, and further acquisition integration initiatives.

Industry Context

Labcorp operates in the diagnostic and biopharma laboratory services industry, which is subject to extensive regulation, competition, and changes in reimbursement policies. The company's performance is influenced by factors such as healthcare reforms, technological advancements, and the demand for laboratory testing services.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific benchmarks or competitor data, it is difficult to assess whether Labcorp's results are above, below, or in line with industry averages.
• A comprehensive industry analysis would require comparing Labcorp's financial metrics (e.g., revenue growth, operating margin) to those of its peers, such as Quest Diagnostics, as well as considering broader industry trends and market conditions.

Legal Proceedings

• The Company is involved in various claims and legal actions, including arbitrations, class actions, and other litigation.
• The Company is defending a lawsuit filed by the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid.
• The Company is defending a putative class action lawsuit, Patty Davis v. Laboratory Corporation of America, et al., filed in the Circuit Court of the Thirteenth Judicial Circuit for Hillsborough County, Florida.
• The Company is responding to a Grand Jury Subpoena issued by the Department of Justice (DOJ) in Miami, Florida requiring the production of documents related to the importation into the United States of live non-human primate shipments originating from or transiting through China, Cambodia, and/or Vietnam from April 1, 2014 through March 28, 2019.
• The Company is defending twenty-three putative class action lawsuits were filed against the Company related to the AMCA Incident in various U.S. District Courts.
• The Company is defending a shareholder derivative lawsuit, Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al., filed in the Court of Chancery of the State of Delaware on April 23, 2020.
• The Company is defending a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Central District of California.
• The Company is defending a patent infringement lawsuit, Ravgen Inc. v. Laboratory Corporation of America Holdings, in the U.S. District Court for the Western District of Texas.
• The Company is defending a putative class action lawsuit, Jose Bermejo v. Laboratory Corporation of America (Bermejo I) filed in the Superior Court of California, County of Los Angeles Central District.
• The Company is defending a Private Attorney General Act lawsuit by the same plaintiff in Jose Bermejo v. Laboratory Corporation of America (Bermejo II), filed in the Superior Court of California, County of Los Angeles Central District.
• The Company is defending a single plaintiff Private Attorney General Act lawsuit, Poole v. Laboratory Corporation of America, filed in the Superior Court of California, County of Kern.
• The Company is defending a putative class action lawsuit, Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds, et al. v. Laboratory Corporation of America, Laboratory Corporation of America Holdings, and Meta Platforms, Inc., filed in the U.S. District Court for the Northern District of California.
• The Company has responded to a Subpoena Duces Tecum issued by the State of Colorado Office of the Attorney General requiring the production of documents related to urine drug testing in all states.
• The Company responded to a Subpoena Duces Tecum issued by the DOJ in Camden, New Jersey requiring the production of documents related to non-invasive prenatal screening tests.
• The Company is cooperating with a Subpoena Duces Tecum issued by the DOJ in Boston, Massachusetts requiring the production of documents related to urine drug testing.

Stakeholder Impact

• Shareholders will receive a cash dividend of $0.72 per share.
• Employees may be affected by restructuring and other charges related to severance and personnel costs.
• Customers may benefit from the company's acquisitions and investments in new technologies.
• The company's legal proceedings and compliance efforts may impact its reputation and financial performance, affecting all stakeholders.

Next Steps

• The company will continue to defend itself in ongoing legal proceedings.
• The company expects to close the acquisition of select assets of BioReference Health's laboratory business in the second half of 2025.
• The company will pay a cash dividend of $0.72 per share on June 11, 2025.
• The company will continue to execute its capital allocation strategy, including share repurchases and dividends.

Key Dates

Keywords

revenue, acquisitions, organic growth, diagnostics, biopharma, earnings, SYNLAB, BioReference Health, dividends, legal proceedings, financial results